6-K 1 d746088d6k.htm FORM 6-K Form 6-K
Table of Contents

 

 

FORM 6-K

 

 

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

Commission File Number: 001-38757

For the month of May 2019

 

 

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(Translation of registrant’s name into English)

 

 

1-1, Nihonbashi-Honcho 2-Chome

Chuo-ku, Tokyo 103-8668

Japan

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

Table of Contents

Information furnished on this form:

EXHIBIT

 

Exhibit
Number

     

1.

    Takeda Announced Candidates for New Directors

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    TAKEDA PHARMACEUTICAL COMPANY LIMITED
Date: May 14, 2019     By:  

/s/ Takashi Okubo

      Takashi Okubo
      Global Head of Investor Relations

Table of Contents

LOGO

   Better Health, Brighter Future

News Release

Takeda Announces Candidates for New Directors

Osaka, Japan, May 14, 2019, — Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has decided the candidates for new Directors which will be proposed to the 143rd Ordinary General Meeting of Shareholders on June, 2019. The candidates are as follows;

 

1.

Candidates for Non-Audit and Supervisory Committee Directors

 

Name

  

Category

  

Current Role

Christophe Weber   Internal   Existing  

                           Representative Director,

                           President & Chief Executive Officer

Masato Iwasaki   Internal   Existing                             Director, President, Japan Pharma Business Unit
Andrew Plump   Internal   Existing                             Director, President, Research & Development
Constantine Saroukos   Internal   New                             Corporate Officer, Chief Financial Officer
Masahiro Sakane   External   Existing                             External Director, Chair of the Board Meeting
Olivier Bohuon   External   Existing                             External Director
Ian Clark   External   Existing                             External Director
Yoshiaki Fujimori   External   Existing                             External Director
Steven Gillis   External   Existing                             External Director
Toshiyuki Shiga   External   Existing                             External Director
Jean-Luc Butel   External   New                             External Director, Audit & Supervisory Committee member
Shiro Kuniya   External   New                             External Director, Head of Audit & Supervisory Committee

Among the above candidates, Jean-Luc Butel and Shiro Kuniya will resign as Audit & Supervisory Committee Directors at the close of the 143rd Ordinary General Meeting of Shareholders.

 

1

Table of Contents
2.

Candidates for Audit and Supervisory Committee Directors

 

Name

  

Category

  

Current Role

Emiko Higashi   External   New                             External Director
Michel Orsinger   External   New                             External Director

Audit & Supervisory Committee Directors (Yasuhiko Yamanaka and Koji Hatsukawa) are within their 2-year tenure, and are not subjects for reelection this year.

 

 

Media Contact:

Kazumi Kobayashi

kazumi.kobayashi@takeda.com

+81 (0) 3-3278-2095

###

 

2